A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers

• Main Authors: Demet Sağlam Aykut, Evrim Özkorumak Karagüzel
• Format: Article
• Language: English
• Published: AVES 2018-07-01
• Series: Psychiatry and Clinical Psychopharmacology
• Subjects: Schizophrenia; metabolic sydrome; second-generation antipsychotics; oral antipsychotics; depot antipsychotics; adverse effect
• Online Access: http://dx.doi.org/10.1080/24750573.2017.1414575

OBJECTIVES: The duration of life of patients with schizophrenia is shorter than that of the general population for various reasons. Especially cardiovascular diseases are one of the most important causes of death in patients with schizophrenia. Our aim in this study is comparison of second-generation depot antipsychotics and second-generation oral antipsychotics used in the treatment of patients with schizophrenia in terms of metabolic syndrome criteria. METHODS: We included 39 patients treated with second-generation depot antipsychotics and 124 patients treated with second-generation oral antipsychotics, who were diagnosed with schizophrenia. Positive and Negative Syndrome Scale was applied to all the patients and blood pressure, weight, height, body mass index, waist circumference, fasting blood glucose, triglyceride level, and high-density lipoprotein (HDL) levels were recorded. RESULTS: In terms of metabolic syndrome criteria, the waist circumference and triglyceride levels of the patients treated with the second-generation depot antipsychotics were lower than those of the patients treated with second-generation oral antipsychotics, and the HDL levels were statistically significantly higher. CONCLUSION: In this study, second-generation depot antipsychotics used in the treatment of schizophrenia patients were found to be associated with more positive results in terms of metabolic syndrome criteria than oral antipsychotic drug forms.